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Abstract
Background: The nature of protective immune responses elicited by immunization
with the candidate malaria vaccine RTS,S is still incompletely understood. Antibody
levels correlate with protection against malaria infection, but considerable variation
in outcome is unexplained (e.g., children may experience malaria despite high anti-
circumsporozoite [CS] titers).
Methods and Findings: We measured the avidity index (AI) of the anti-CS
antibodies raised in subgroup of 5–17 month old children in Kenya who were
vaccinated with three doses of RTS,S/AS01E between March and August 2007. We
evaluated the association between the AI and the subsequent risk of clinical
malaria. We selected 19 cases (i.e., with clinical malaria) and 42 controls (i.e.,
without clinical malaria), matching for anti-CS antibody levels and malaria
exposure. We assessed their sera collected 1 month after the third dose of the
vaccine, in March 2008 (range 4–10 months after the third vaccine), and at 12
months after the third vaccine dose. The mean AI was 45.2 (95% CI: 42.4 to 48.1),
45.3 (95% CI: 41.4 to 49.1) and 46.2 (95% CI; 43.2 to 49.3) at 1 month, in March
2008 (4–10 months), and at 12 months after the third vaccination, respectively
(p50.9 by ANOVA test for variation over time). The AI was not associated with
protection from clinical malaria (OR50.90; 95% CI: 0.49 to 1.66; p50.74). The AI
was higher in children with high malaria exposure, as measured using the weighted
local prevalence of malaria, compared to those with low malaria exposure at 1
month post dose 3 (p50.035).
Conclusion: Our data suggest that in RTS,S/AS01E-vaccinated children residing in
malaria endemic countries, the avidity of anti-circumsporozoite antibodies, as
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measured using an elution ELISA method, was not associated with protection from
clinical malaria. Prior natural malaria exposure might have primed the response to
RTS,S/AS01E vaccination.
Introduction
RTS,S consists of 19 copies of the central tandem repeats and C-terminal region of
the P. falciparum circumsporozoite protein (CS) fused to hepatitis B surface
antigen (HBsAg), and co-expressed with unfused HBsAg in Saccharomyces
cerevisiae cells [1]. The protein encodes both B and T cell epitopes. The antigen is
administered with Adjuvant system (AS01), a liposome-based adjuvant system
that contains 3-O-desacyl-49-monophosphoryl lipid A and the saponin Quillaja
saponaria Molina, fraction 21 ‘‘(QS21, Antigenics Inc., a wholly owned subsidiary
of Agenus Inc., Lexington, MA, USA)’’.
RTS,S is highly immunogenic [2, 3, 4, 5], inducing both high titers of CS
antibodies (anti-CS) and CS-specific CD4 T cell responses. There is evidence that
anti-CS titers correlate with protection in controlled human malaria infection in
malaria-naı¨ve adults [2, 6], and natural malaria infection in adults and children in
malaria-endemic regions [7, 8]. We have recently demonstrated a non-linear
association between anti-CS titers and protection from clinical malaria in children
5–17 months residing in malaria-endemic countries [9], and in children aged 6–
10 weeks anti-CS titers were found to be correlated with protection from clinical
malaria [10]. However there was no association between anti-CS titers and
protection from clinical malaria in children 1–4 years old in Mozambique [11].
Even in trials where correlations between anti-CS titers and outcome were
observed, considerable variation in outcome remained unexplained (e.g. children
may experience malaria despite high titers). Some studies suggest an association
between cell-mediated immune responses (specifically CD4 T cell responses) and
protection against clinical malaria in children, albeit of lesser importance than
antibody responses [12]. However, substantial variability in protection remains
unexplained even after accounting for anti-CS antibody and CD4 T cell responses
(i.e. there are unprotected children with high titer antibodies and strong CD4 T
cell responses).
In addition to the quantity of antibodies, quality of antibodies may determine
protection following vaccination against diverse pathogens [13]. In early phase of
adaptive immune response antibody-secreting cells usually produce antibodies of
low affinity. These cells then proliferate within germinal centers where somatic
hypermutation of V(D)J immunoglobulin gene and antigen-driven selection of
high-affinity antibody-producing B cells occurs. Antibody affinity is difficult to
measure since it requires monoclonal antibodies, purified antigen, and it must be
carried out under strict chemical conditions. However antibody avidity can be
used as the surrogate marker for affinity following vaccination. Avidity is defined
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as the antigen binding capacity resulting from the addition of all epitope-specific
affinities of antibodies in a serum [14]. High avidity antibodies appear important
in the protection conferred by Haemophilus influenza type b vaccine, Hepatitis B
vaccine and Pneumococcal conjugate vaccine [15, 16, 17]. The avidity of anti-CS
antibody contributes to protection against malaria in a mouse model [18].
To date, no study has investigated the role of avidity of RTS,S-induced anti-CS
antibodies in protection against malaria infection among RTS,S vaccinees in the
field. Here we report the results of such study in children 5–17 month residing in
Kilifi, Kenya who were immunized with RTS,S/AS01E.
Materials and Methodology
Vaccine and subjects
Serum samples from a phase IIb randomized controlled trial originally designed to
determine the efficacy of RTS,S/AS01E against Plasmodium falciparum clinical
malaria in 5–17 month old children were used (ClinicalTrials.gov number,
NCT00380393) [12, 19]. All children received all three doses of RTS,S/AS01E
between March and August 2007. The candidate vaccine was given intramuscu-
larly in the right deltoid area in a 0, 1, 2 month schedule. Blood samples were
collected at screening, at 1 month after the third dose of vaccine, in March 2008
(range 4–10 months (mean 8 months) post dose 3) and at 12 months after the
third dose of vaccine for the assessment of antibodies to P. falciparum CS repeat
region (anti-CS antibodies).
Informed written consent was obtained from parents of the study participant
using approved Swahili or Giriama consent forms. All the parents signed the
informed consent and were provided with the copy of informed consent and
participant information sheet. Illiterate parents thumb printed the forms with
independent literate witness countersigning. The original study was approved by
the Kenya Medical Research Institute National Ethics Committee, Western
Institution Review Board and Oxford Tropical Research Ethics Committee.
Study design
A nested case-control study was conducted to investigate the association between
vaccine-induced anti-CS antibody avidity and protection from clinical malaria.
Cases were defined as children who had at least one episode of clinical malaria
(axillary temperature $37.5 C˚ and P falciparum parasitaemia .2500/mL) during
the 15 months of follow-up beginning 2 weeks after the 3rd dose of vaccine while
controls were children who did not experience any clinical malaria episodes.
The study was conducted in villages of Junju and Pingilikani in Kilifi district.
The two areas have moderate malaria transmission based on parasite prevalence
rates [20]. Malaria exposure was measured as the weighted local prevalence of
malaria cases within a 1 km radius of each index child, or ‘‘exposure index’’, as
previously described [21]. Malaria exposure was considered ‘‘high’’ if the
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exposure index was above the cohort mean and ‘‘low’’ if the exposure index was
below the cohort mean.
Due to cost and allowable time to accomplish the study, only a fraction of the
available samples could be analyzed. We randomly selected 19 cases and 42
controls from 295 RTS,S/AS01E vaccinees with immunogenicity data matching
for the level of peak anti-CS levels and malaria exposure. The selected sample size
was enough to provide 80% power to detect an odds ratio of 3 between cases and
controls given 50% probability of exposure (antibody avidity with protective
effect) among controls and an alpha of 0.05. In an exploratory analysis we
compared the avidity indices of controls (protected children) who had low
antibody level (in the lower tertile) and high malaria exposure with cases to
determine if the avidity index could explain the protection. All selected cases and
controls had their samples assessed for the anti-CS avidity at three time points i.e.
1 month, March 2008 (range 4–10 months) and at 12 months post dose three.
Avidity was not measured in screening samples because anti-CS titers were
undetectable before vaccination.
Anti-CS antibody titers
Anti-CS antibody titers were determined by standard enzyme-linked immuno-
sorbent assay (ELISA) developed by GSK Biologicals [22]. Plates were adsorbed
with the recombinant antigen R32LR, which contains the sequence
[NVDP(NANP)15]2LR and antibody titers were calculated using a reference
standard curve and expressed in ELISA units (EU) per mL. A cut-off point for
positive titers was 0.5 EU/mL.
Anti-CS avidity assay
We used a single concentration ammonium thiocyanate (NH4SCN) elution ELISA
to determine the avidity of the polyclonal anti-CS antibodies. Polystyrene
microtiter plates were coated overnight at 4 C˚ with 2.5 mg/ml R32LR protein in
coating buffer. Following washing, the plates were blocked with 200 ml PBS-5%
skim milk per well for 1 hour at 25 C˚ in a horizontal orbital shaker (Skatron 300).
We conducted 8-fold serial dilutions in duplicate. A pre-dilution at 1:100 was
done for all serum samples with anti-CS titer above 200 EU/mL before the
beginning of serial dilutions. Serum samples with anti-CS titer below 200 EU/mL
were not pre-diluted. Standard (serum from malaria naı¨ve adult vaccinated with
R32LR attributed an arbitrary value of 109 EU/mL provided by GSK Vaccines),
negative control (i.e. anti-CS negative serum from malaria naı¨ve adult provided
by GSK Vaccines) and positive control (i.e. a pool of anti-CS human sera
approximately at 100 EU/ml that demonstrated an AI of 43.1¡3.8, provided by
GSK Vaccines) were added in each plate and serially diluted like samples. The
plates were then incubated for 2 hours at 37 C˚.
Each serum sample was processed in two different plates; one treated with
NH4SCN, and one untreated plate. Both plates were washed twice with 0.05%
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Tween-20 in PBS (wash buffer). A 1 M solution of NH4SCN in laboratory grade
water was added in the treatment plate while 0.05% Tween-20 in PBS was added
in the control plate and both were incubated for 30 min at 25 C˚. The plates were
then washed three times with wash buffer. After a third wash, anti-human IgG
conjugated to horseradish peroxidase (HRP) was added and incubated for 30 min
at 25 C˚ before washing. After 30 min incubation with chromogen substrate
(3,39,5,5 Tetramethylbenzidine [TMB] and H2O2) at 25 C˚ (yielding a blue color),
the reaction was stopped with 50 ml of 1 N sulphuric acid changing the color to
yellow. The intensity of the color was proportional to the titer of the anti-CS IgG
antibodies contained in the sample. Absorbance at 450 nm was read by use of an
automatic microtiter plate reader. Samples Optical densities (OD’s) were
converted into EU/ml using a standard curve at the linear segment of the curve
and mean values used to estimate avidity index. Linearity of the assay was
demonstrated by the observation that for a high concentration sample, serially
diluted sample was able to reproduce the same Avidity Index (AI) over the entire
anti-CS analytical range. The AI is defined as the ratio of the quantity of anti-CS
antibodies (in EU/ml) that remained bound to the coated antigen after treatment
with NH4SCN divided by the quantity of antibodies (in EU/ml) that remained
bound to the coated antigen in the control plate. The AI for each serum represents
the composite value across all the dilutions.
TNF-a-producing CD4 T-cells immune response
Whole-blood intracellular staining assay was used to determine the frequency of
CD4 T cells producing TNF-a as previous described [12]. Stimulation of blood
was done within 3 hours after blood withdrawal and samples were stored 3 to 4
months before staining.
Statistical Analysis
Anti-CS avidity measures were not transformed in the analysis and were presented
as percentage (by multiplying the ratio by 100). The anti-CS titers and avidity
indices were presented for each group as arithmetic mean¡95% confidence
interval per group. Students T-test was used to compare the avidity indices and
antibody titers between groups. A one-way analysis of variance (ANOVA) was
used to test for the difference in antibody titers and antibody avidity during follow
up (1 month, ,8 and 12 months post dose three). Unconditional logistic
regression analysis was used to estimate odds ratios (ORs) and 95% Confidence
intervals adjusting for TNFa-producing CD4 T cells, bed net use and malaria
exposure (high or low). Cluster sandwich covariance matrix estimator was used to
account for the multiple entries per child. No adjustment was made for the
variable (i.e. anti-CS titers) used to select cases and controls to avoid bias. All
analyses were done in STATA (version 12; Stata Corp).
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Results
All children received all three doses of RTS,S/AS01E between March and August
2007.
A total of 162 sera (50 sera obtained 1 month post dose 3, 51 sera obtained on
March 2008 (range; 4–10 months post dose 3) and 61 sera obtained 12 month
post dose 3) from 61 study participants were available for the analysis.
The geometric mean titer of anti-CS titer in a subset of children in this study 1
month after the third vaccination was 732.1 EU/mL (95% CI, 608.4 to 880.8) and
this fell to 105.3 EU/mL (95% CI, 83.8 to 132.3) and 64.7 EU/mL (95% CI, 50.4 to
83.1) at 6.5 month and 12 month post vaccination 3 respectively (F test5125
p,0.001 by ANOVA test). The dynamics of anti-CS titers in cases and controls is
shown in Fig. 1 (Panel A).
Anti-CS avidity
The arithmetic mean AI of polyclonal anti-CS antibodies at 1 month, March 2008
(,8 months) and 12 months post dose 3 was 45.2 (95% CI: 42.4 to 48.1), 45.3
(95% CI: 41.4 to 49.1) and 46.2 (95% CI; 43.2 to 49.3), respectively (Table 1). The
AI did not differ between the three time points (F test50.12 p50.9 by ANOVA
test).
Correlations were observed between the AI at 1 month post-dose 3 and at ,8
months post-dose 3 (r50.33, p50.0111), as well as at 1 month and 12 months
post-dose 3 (r50.48, p50.0002) (Fig. 1, Panel B).
There was no correlation between the AI and anti-CS titers at all three time
points (r5–0.03; p50.859, r50.05; p50.704 and r50.16; p50.220) or between
the AI and age at vaccination (r50.003, p50.656) (Fig. 1, Panel C and Panel D
respectively).
Avidity and protection from clinical malaria
The AI in cases and controls at 1, ,8 and 12 months post dose three is shown in
Table 1. The AI at all time points was not different from those recorded in cases
and controls (F test52.69, p50.103 by ANOVA) (Table 1). In an exploratory
analysis, we showed that avidity indexes indices among controls (i.e. children
without episodes of malaria or the ‘‘protected group’’) were similar to cases (i.e.
children with malaria) (Table 1).
The unadjusted odds ratio for clinical malaria was 1.36 (95% CI: 0.89 to 2.1;
p50.165) for each 10% increase in avidity index, indicating that we had power to
exclude an OR of ,0.89. Multivariable logistic regression showed no association
between the avidity index and protection from clinical malaria (Table 2). TNF-
alpha producing CD4 T cells were independently associated with decreased risk of
malaria (OR50.63, p value50.027) while malaria exposure was associated with
increased risk for clinical malaria (OR511.24, p value50.005).
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Avidity and malaria exposure
The AI at 1 month post dose 3 was higher in children under high malaria exposure
conditions compared to those under low malaria exposure with borderline
statistical significance (48.6%, 95% CI: 45.4 to 51.8, versus 42.8%, 95% CI 38.2 to
Fig. 1. Panel A: Anti-CS titers in cases, controls and 19 protected children with low anti-CS antibodies titer and high malaria exposure index
during 15 months of follow-up. Panel B: Matrix diagram showing correlation between antibody avidity measured at three time points during the follow up.
Significant correlation observed between AI at 1 month post-dose 3 and at,8 months post-dose 3 (r50.33, p value50.0111) and at 1 month and 12 months
post-dose 3 (r50.48, p value50.0002). Panel C: Correlation between anti-CS antibody avidity at 1 month post dose 3 and age (r50.003, p value50.656)
Panel D: Correlation between anti-CS antibody avidity and anti-CS antibody titers at 1 month post dose 3 (r5–0.03; p value50.859).
doi:10.1371/journal.pone.0115126.g001
Table 1. Avidity indices in cases, controls and a subset of 19 controls with high exposure rates and low anti-CS titers at different sampling times.
Sampling time Months
after 3rd vaccine dose
Cases Avidity
index (95% CI) Controls Avidity index (95% CI) P value*
All
High exposure
and low anti-CS titer
1 47.1
(42.8–51.4)
44.6
(38.6–50.6)
44.4
(39.4–49.4)
0.418
,8 48.4
(43.8–52.9)
42.2
(33.9–50.4)
45.2
(37.5–52.9)
0.254
12 48
(43–53)
44.7
(39.2–50.1)
46.3
(40.1–52.4)
0.423
CI: Confidence Intervals.
*p value for the comparison between cases and controls (all).
doi:10.1371/journal.pone.0115126.t001
Avidity of RTS,S-Specific Antibodies
PLOS ONE | DOI:10.1371/journal.pone.0115126 December 15, 2014 7 / 15
47.4, p50.035 by Students T test) (Fig. 2). This difference was also observed at,8
months; 47.9% (95% CI: 42.4 to 53.5) versus 43.2% (37.6 to 48.8) p50.2167 and
at 12 months; 48.2% (95% CI: 44.3 to 52.1) versus 45.3% (95% CI: 40.6 to 49.9)
p50.3361 post dose 3 but these were not statistically significant.
Discussion
The nature of protective immune responses elicited by immunization with RTS,S
is still incompletely understood. Although RTS,S-induced humoral and cell
mediated immune responses correlate with protection against both asymptomatic
and symptomatic parasitaemia [2, 9, 23], there is substantial variation in the rate
of protection within individuals displaying similar level of immune responses.
Here, we show that antibody avidity is not associated with protection from clinical
malaria among RTS,S/AS01E vaccinees with similar levels of anti-CS antibodies
aged 5–17 months and residing in a malaria endemic country.
There was no evidence of anti-CS avidity maturation beyond one month post
dose 3. Avidity maturation follows B cells activation in a CD4 T cell dependent
manner and is the hallmark of immunologic memory [13]. However there is
substantial variability in the capacity of vaccines to evoke avidity maturation [24].
Following Hepatitis B vaccination no avidity maturation was observed beyond the
third dose although significant increase in avidity occurred between the first and
the third dose [15]. Avidity maturation persisted between the third and fourth
dose of meningococcal serogroup C (MCC) conjugated vaccine, but there was no
change in antibody avidity beyond the fourth dose [25]. In our setting, the avidity
maturation process may have been complete by 1 month post dose three. Since
avidity maturation has only been evaluated after the third dose, no information is
available of its evolution following the preceding doses. Factors such as the type of
method and chaotropic agent used, chaotropic agent concentration, chaotropic
incubation time and temperature of the reaction [26] can influence the avidity
results making comparison across the studies and methods difficult. Avidity index
of antibodies to GMZ2 (a hybrid protein consisting of the N-terminal region of
the glutamate-rich protein fused in frame to the C-terminal region of merozoite
surface protein 3) after three doses was 35% (95% CI 30% to 42%), slightly lower
than what we observed for RTS,S induced antibodies. Similarly, the avidity of
naturally acquired antibodies to AMA-1 and MSP-1 antigens in children residing
Table 2. Multivariable logistic regression analysis for the effect avidity on clinical malaria.
Variables Odds Ratio (95% CI) P value
Avidity (per 10% increase in avidity). 0.90 (0.49–1.66) 0.744
CD4+-TNF-a cells
(per 10-fold increase in frequency)
0.63 (0.41–0.95) 0.027
Bed net 1.39 (0.42–4.58) 0.588
Malaria exposure 11.24 (2.08–60.68) 0.005
doi:10.1371/journal.pone.0115126.t002
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in malaria endemic country were considerably lower (median of 13% and 15%
respectively) compared to RTS,S induced antibodies to CSP [27]. However both
studies used different chaotropic agents (diethylamine and guanidine hydro-
chloride, respectively) and incubation times (15 and 10 minutes respectively).
Potent novel adjuvant (AS01) co-administered with the vaccine and the virus-like
particle nature of the RTS,S may explain the high avidity observed in comparison
with other studies [28, 29].
We found no association between avidity and protection from clinical malaria.
Data in one animal model (P. berghei) suggests that induction of sterile immune
responses by CSP-based subunit vaccines depends on inducing antibody of the
appropriate isotype, specificity and avidity [30]. A study in another animal model
(P. yoelii) found protection against sporozoite challenge to be independent of
antibody avidity and/or isotype [31]. In contrast high affinity antibodies to
Plasmodium falciparum merozoite antigens measured by surface plasmon
resonance technology have been shown to be protective [32]. One possible
explanation for lack of correlation between avidity and protection in the present
study may be that the majority of the antibodies induced by three doses of RTS,S/
AS01E had exceeded a minimum avidity threshold required for protection and
hence we could not detect any variation in outcome. For instance, Bachmann et
al. observed lack of correlation between antibody avidity and protection against
vesicular stomatitis virus (VSV) once the antibody avidity had reached a
minimum threshold [33]. The AI was significantly higher in children with high
malaria exposure compared to those with low malaria exposure. In theory, this
Fig. 2. Box plot of anti-CS antibody avidity by level of malaria exposure (based on malaria exposure
index) at 1, ,8 and 12 months post dose 3.
doi:10.1371/journal.pone.0115126.g002
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could be due to progressive anti-CS avidity maturation as a consequence of
natural infection and boosting by repeated malaria exposure early in life (prior to
vaccination). However, there is no evidence of boosting of RTS,S-induced
immune responses by natural exposure in previous studies, and the avidity did
not increase over the duration of the study. In fact we found no evidence of
avidity maturation of anti-merozoite antibodies with increasing natural malaria
exposure in individuals residing in the study area [27]. Alternatively, prior
exposure to malaria (as measured using our exposure index) may have primed
children to respond with higher avidity antibodies on vaccination [34]. Thus,
those with higher exposure may have had higher frequencies of naturally acquired
anti-CS memory B cells with higher receptor affinities than those with low
exposure. In keeping with this suggestion is the finding that the correlation
between AI and malaria exposure was only significant at 1 month post dose 3 and
not at subsequent time points. The trial provided insecticide treated bed nets to all
study participants at the start of the trial. Although the use of the bed net declined
over time, it remained above 70% and we did not find association between bed
net use and protection from malaria.
Although avidity was associated with exposure to malaria, there was no
indication that avidity might be protective in our case control analysis either with
or without adjusting for exposure (Table 2). Among the group of vaccinated
children who remained free of clinical malaria episodes despite low antibody titers
and apparent exposure to malaria as determined by the exposure index, the
avidities were no higher than the randomly selected cases and controls (Table 1).
Taken together with our case control analysis (in which we confirmed a previously
identified association between protection and cellular immunity) [12, 19], our
results suggest that avidity, as measured using an elution ELISA method, does not
play a role in determining outcome in the field. Studies where vaccinees are
exposed to controlled human malaria infection suggest that antibody levels are
more strongly associated with protection than cellular immunity [35].
We used an elution assay with single thiocyanate concentration and serially
diluted sera. The method has been extensively used to measure the avidity of
various vaccine antigens [14, 24, 36]. The method is devoid of many limitations
encountered by an elution method using multiple concentrations of thiocyanate
with single sera dilutions. Such limitations include discrepancies in OD results at
lower thiocyanate concentration and inability to take into account the effect of
serum concentration on the binding of antigen [36]. Surface Plasmon resonance
(SPR) is a new technique which has recently been used to measure the avidity of
malaria specific antibodies [32]. It measures the binding capacity of an antibody
under flow, mimicking the in vivo environment [37]. Studies have shown that the
Surface Plasmon resonance does not necessarily correlate with results from
thiocyanate avidity assays [32] and therefore further investigation using this new
technique may be justified.
We did not observe any correlation between age of the child and antibody
avidity or between antibody avidity and antibody levels. Study evaluating the
affinity of naturally acquired blood stage antigens using SPR and elution ELISA
Avidity of RTS,S-Specific Antibodies
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found positive correlation between antibody levels and its affinity for high but not
low affinity antibodies [32]. Despite declining anti-CS titers, antibody avidity was
sustained throughout the 15 months of follow-up. Although quantity of antibody
may reflect the immediate response to a vaccine, quality of antibody response may
be more important in determining the immune status months after vaccination.
However Bachmann et al noticed that low avidity antibodies required very high
concentration to achieve desired effectiveness [33], which may suggest that
increasing and maintaining high antibody titres could be an important strategy to
improve and sustain the efficacy of RTS,S.
TNF-alpha producing CD4 T cell responses were independently associated with
protection. There was no interaction between avidity and TNF-alpha producing T
cells (odd ratio for interaction term50.77, p value50.319). However CD4 T cells
are known to play an important role in antibody affinity maturation through their
interactions with cognate B-cells [38].
There are other qualitative aspects of the antibody responses that we did not
examine; such as the IgG isotypes in the children and ability of antibodies to
inhibit hepatocyte infection in functional assays. IgG3 and IgG1 are the most
effective isotypes at mediating antibody-dependent cellular mechanisms like
phagocytosis and complement fixation against blood stage malaria antigens, and
have been associated with protection from clinical malaria in the field [39, 40, 41].
On the other hand IgG2 may compete with IgG1 and IgG3 and interfere with their
activity [42]. Thus, similarly in the case of RTS,S immunization the isotype
distribution of the induced response may determine the mechanism by which
sporozoites may be taken up and destroyed by monocytes and macrophages [43].
Although the anti-CS antibody response induced by RTS,S in naı¨ve adults is
skewed towards IgG1 and IgG2 [44], the isotype distribution in children is
unknown. It is also worth noting that our analysis focused on the antibodies to the
central repeat region of the RTS,S and not antibodies to the C- terminal flanking
region. This potentially excludes some relevant antibody responses which could
explain the effectiveness of the vaccine [45]. However, antibodies to repeat CS
have been shown to neutralize the infectivity of the sporozoite both in vivo and
in vitro [46, 47, 48] and CS repeat region is regarded as the major immunodo-
minant epitope [49, 50].
Our assays measured average avidity of specific polyclonal serum antibodies
which comprise of a mixture of antibody subpopulations with different avidities.
Avidity indices can vary considerably with each sample and this can only be well
depicted by avidity distribution. We cannot comment on this possibility given
that we did not store the data in a manner to enable the performance of this
analysis.
In conclusion, antibody avidity did not predict protection in RTS,S/AS01E
vaccinees with similar levels of anti-CS titers Antibody avidity was higher in
children with high malaria exposure suggesting a possible priming effect of
natural infection on the RTS,S-induced response.
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